Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
Campus

Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases

Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.

Related articles
Hear from an expert on what does Dupixent bring to your practice?
  • Nasal Polyps

Hear from an expert on what does Dupixent bring to your practice?

Read article
Expert opinions: Would you consider a biologic for a CRSwnp patient who has had Sinus surgery?
  • Nasal Polyps

Expert opinions: Would you consider a biologic for a CRSwnp patient who has had Sinus surgery?

Read article
Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?
  • Nasal Polyps

Hear from an expert on how does Dupixent target Underlying Type 2 Inflammation?

Read article
MAT-BH-2300373/V1/JUNE 2023